US 11,691,950 B2
Isoquinoline-steroid conjugates and uses thereof
Mitchell A. deLong, Chapel Hill, NC (US); Eric Carlson, Irvine, CA (US); Casey Kopczynski, Chapel Hill, NC (US); Jill M. Sturdivant, Chapel Hill, NC (US); and Cynthia Lichorowic, Raleigh, NC (US)
Assigned to Aerie Pharmaceuticals, Inc., Bedminster, NJ (US)
Filed by Aerie Pharmaceuticals, Inc., Bedminster, NJ (US)
Filed on Jun. 4, 2021, as Appl. No. 17/339,828.
Application 17/339,828 is a division of application No. 16/557,779, filed on Aug. 30, 2019, granted, now 11,059,789.
Claims priority of provisional application 62/725,941, filed on Aug. 31, 2018.
Prior Publication US 2021/0300874 A1, Sep. 30, 2021
Int. Cl. C07D 217/22 (2006.01); A61K 47/28 (2006.01); A61K 9/00 (2006.01)
CPC C07D 217/22 (2013.01) [A61K 47/28 (2013.01); A61K 9/0048 (2013.01)] 18 Claims
 
1. A method of treating an eye disease or disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound having the formula:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.